OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers

Journal of Clinical Pharmacy and Therapeutics

Volumn 35, Issue 1, 2010, Pages 99-104

  Wen, J ^a   Xiong, Y ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

388A>G; Liquid chromatography mass spectrometry; Organic anion transporting polypeptide 1B1; Pharmacokinetic; Pitavastatin; Polymorphism

Indexed keywords

ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 1B1; PITAVASTATIN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CHINESE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG TRANSPORT; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PROTEIN POLYMORPHISM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; TIME TO MAXIMUM PLASMA CONCENTRATION;

GENETIC ASSOCIATION STUDIES; HALF-LIFE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; METABOLIC CLEARANCE RATE; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, SINGLE NUCLEOTIDE; QUINOLINES;

EID: 74349126111     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2009.01071.x     Document Type: Article

References (20)

1. Isley WL (2001) Pitavastatin (NK-104), a new HMG-CoA reductase inhibitor. Drugs Today, 37, 587 594.
2. Kajinami K, Takekoshi N, Saito Y (2003) Pitavastatin: Efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovascular Drug Reviews, 21, 199 215.
3. Corsini A, Bellosta S, Baetta R et al. (1999) New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacology and Therapeutics, 84, 413 284.
4. Fujino H, Yamada I, Shimada S et al. (2003) Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP- glucuronosyltransferase enzymes involved in lactonization. Xenobiotica, 33, 27 41. (Pubitemid 36071761)
5. Fujino H, Yamada I, Kojima J et al. (1999) Studies on the metabolic fate of NK-104, a new inhibitor HMG-CoA reductase (5): In vitro metabolism and plasma protein binding in animals and human. Xeno Metab Disp, 14, 415 424.
6. Fujino H, Kojima J, Yamada I et al. (1999) Studies on the metabolic fate of NK-104, a new inhibitor HMG-CoA reductase (5): Interspecies variation in laboratory animals and humans. Xenobiol metab Dispos, 14, 79 81.
7. Fujino H, Yamada I, Shimada S et al. (2000) Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase-effect of Cmoat deficiency on hepatobiliary excretion in rats and of mdr 1ab gene disruption on tissue distribution in mice. Drug Metabolism Pharmacokinetics, 17, 449 456.
8. Hirano M, Maeda K, Shitara Y et al. (2004) Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. The Journal of Pharmacology and Experimental, 311, 139 146.
9. Hagebuch B, Meier PJ (2003) The superfamily of organic anion transporting polypeptides. Biochimica et Biophysica Acta, 1609, 1 18.
10. Nakai D, Nakagomi R, Furuta Y et al. (2001) Human liver-specific organic anion transporter, LST-1, mediates take of pitavastatin by human hepatocytes. Journal of Pharmacology and Experimental Therapeutics, 297, 861.
11. Chung JY, Cho JY, Yu KS et al. (2005) Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clinical Pharmacology and Therapeutics, 78, 342 350.
12. Ieiri I, Suwannakul S, Maeda K et al. (2007) SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clinical Pharmacology and Therapeutics, 82, 541 547.
13. Jada SR, Xiaochen S, Yan LY et al. (2007) Pharmacogenetics of SLCO1B1: haplotypes, htSNPs and hepatic expression in three distinct Asian populations. European Journal of Clinical Pharmacology, 63, 555 563.
14. Tirona RG (2005) Ethnic differences in statin disposition. Clinical Pharmacology and Therapeutics, 78, 330 341.
15. Kim EY, Cho DY, Shin HJ (2008) Duplex pyrosequencing assay of the 388A>G and 521T>C SLCO1B1 polymorphisms in three Asian populations. Clinica Chimica Acta, 388, 68 72.
16. Xu LY, He YJ, Zhang W (2007) Organic anion transporting polypeptide-1B1 haplotypes in Chinese patients. Acta Pharmacologica Sinica, 28, 1693 1697.
17. Pasanen MK, Neuvonen PJ, Niemi M (2008) Global analysis of genetic variation in SLCO1B1. Pharmacogenomics, 9, 19 33.
18. Shitara Y, Sugiyama Y (2006) Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy -3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacology and Therapeutics, 112, 71 105.
19. Nishizato Y, Ieiri I, Suzuki H et al. (2003) Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes consequences for pravastatin pharmacokinetics [J]. Clinical Pharmcology Therapeutics, 73, 554 565. (Pubitemid 37249126)
20. Lee E, Ryan S, Birmingham B et al. (2005) Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clinical Pharmacology and Therapeutics, 78, 330 341.